Per Norlén was born on1970. He is CEO since 2015 and Chief Medical Officer (CMO) since 2010. He is a registered medical doctor with a doctoral degree and specialist doctor in clinical pharmacology, and associate professor in experimental and clinical pharmacology at Lund University. Per Norlén has 25 years of research experience in pharmacology including 14 years of experience in clinical drug development with a focus on clinical phase I/II studies. Member of the Management Team since 2010. He is also Board member of Atlas Therapeutics AB and A Bioscience Incentive AB.
Haematology